EDN1 and pulmonary arterial hypertension: Although ET-1 may play a role in the pathophysiology of PH-HFpEF, the results of using FDA-approved endothelin receptor antagonists for the treatment of PAH have been rather disappointing in the treatment of patients with PH-HFpEF.